報價延遲最少15分鐘:2025/07/20 16:41 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.09 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.07/-2.89
|
|
企業價值
1.04B
|
| 資產負債 |
|
每股賬面淨值
5.39
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 16:41 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA. |
